当前位置：
发布日期：2015-06-01 来源：本站原创 浏览量：
报告题目：The Application of PK/PD Modeling in Clinical Drug Development (药代谢动力学和药效学模型在临床药物研发中的应用)
报告时间：2015年6月2日（周二）9:00 – 11:00
报告地点：主楼三楼会议室
报 告 人：闫晓宇 博士Senior Scientist
（Johnson & Johnson Pharmaceutical Research & Development）
主 持 人：游松教授
主办单位：微生物与生化教研室
研究生处（学科建设办公室）
辽宁省研究生现代药物领域创新与交流中心
聆听无涯论坛 拓宽学术视野
欢迎各位老师和同学们踊跃参加！
报告人简介
XIAOYU YAN
Ph.D
920 Route 202 South, Raritan, NJ 08869
(908) 927-2659 (office)
xyan14@its.jnj.com
EMPLOYMENT
|
Apr. 2015-Present
|
Senior Scientist
Model Based Drug Development, Quantitative Science, Johnson & Johnson Pharmaceutical Research & Development |
|
Jan. 2013-Mar.2015
|
Scientist
Model Based Drug Development, Quantitative Science, Johnson & Johnson Pharmaceutical Research & Development |
|
Aug. 2012-Jan. 2013 |
Scientist
Global Clinical Pharmacology, Johnson & Johnson Pharmaceutical Research & Development |
EDUCATION
|
Aug. 2006-May 2012 |
Ph.D, Pharmaceutical Science
University at Buffalo, The State University of New York, Buffalo |
|
|
|
|
|
|
Dec. 2003-Aug. 2006 |
M.Sc., Pharmaceutical Sciences
University of Saskatchewan, Saskatoon, Canada |
|
|
|
|
|
|
Sep. 2000-Jul. 2003 |
M.Sc., Pharmaceutical Sciences
Shenyang Pharmaceutical University, Shenyang, P.R. China |
|
|
|
|
|
|
Sep. 1996-Jul. 2000 |
B.Eng., Pharmaceutical Sciences
Shenyang Pharmaceutical University, Shenyang, P.R. China |
|
PUBLICATIONS
1. {C}Genovese M, Hsia E, Belkowski SM, Chien C, Masterson T, Thurmond RL, Manthey CL, Yan X, Ge T, Franks C, Greenspan A. Results From a Phase 2a, Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug Therapy. (Submitted)
2. {C}Yan X and Krzyzanski W. Quantitative assessment of minimal effective concentration of erythropoiesis-stimulating agents. CPT Pharmacometrics Syst Pharmacol. 2013; 2:e62.
3. {C}Yan X, Ait-Oudhia S, Krzyzanski W. Erythropoietin-induced erythroid precursor pool depletion causes erythropoietin hyporesponsiveness. Pharm Res. 2013 ;30(4):1026-36
4. {C}Yan X, Chen Y, Krzyzanski W. Methods of solving rapid binding target-mediated drug disposition model for two drugs competing for the same receptor. J Pharmacokinet Pharmacodyn. 2012; 39(5):543-60
5. {C}Yan X and Krzyzanski W. Dose correction for the Michaelis-Menten approximation of the target-mediated drug disposition model. J Pharmacokinet Pharmacodyn. 2012; 39(2):141-6
6. {C}Yan X, Lowe P, Fink M, et al. Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human epoetin alfa and the biosimilar HX575. J Clin Pharmacol. 2011; 52(11):1624-44 (McKeen Cattell Memorial Award for Best Paper 2013)
7. {C}Yan X, Mager DE, Krzyzanski W. Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models. J Pharmacokinet Pharmacodyn. 2010; 37:25-47 (Cover Feature)
8. {C}Yan X, Wang H, Yao X, et al. Identification of a protein interacting with Shigella flexneri IpaC invasin by yeast two-hybrid system. Acta Genetica Sinica 2004; 31:369-374
9. {C}Yan X, Wang H, You S, Huang L. The application of differential fluorescence induction in screening in vivo induced genes of bacteria. Letters In Biotechnology, 2003; 14: 324-327
10. {C}Yao X, Wang H, Yan X, et al. The cloning of ipab gene from Shigella flexneri and its expression in yeast cell. Acta Microbiologica Sinica 2003; 43:418-421
11. {C}Yao X, Wang H, Shi Z, Yan X, et al. Identification of RanBMP interacting with Shigella flexneri IpaC invasin by two-hybrid system of yeast. World J Gastroenterol. 2003; 9:1347-1351
12. {C}Yao, X., Wang, H., Shi, Z., Yan, X., et al. Construction of SW480 cell model identifying Shigella virulent genes. Yi Chuan, 2004; 26(4):495-8.
13. {C}Yao, X., Wang, H.,Yang, B, Yan, X., et al. Cloning and sequencing of ipaC gene from Shigella flexneri. Journal of Shanxi Normal University (Nature Science Edition), 2003; 2: 89-91.